Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975000 · ClinicalTrials.gov registry record · Phase 3
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT00975000: Completed Phase 3 study, sponsored by Amgen.
NCT00975000 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 114 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00975000, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT may include increases in blood levels of calcium (hypercalcemia) and low blood levels of phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation, itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant dysfunction (worsening of kidney transplant function). The purpose of this study is to evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in patients with HPT after a kidney transplant.
Interventions
- DRUG Placebo
- DRUG Cinacalcet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2009-12-03 |
| Est. Completion | 2013-04-16 |
| Phase | Phase 3 |
What the finished NCT00975000 record still lists
NCT00975000 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00975000 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00975000 about?
NCT00975000 is a clinical study titled "Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients". Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures,...
What is the current status of trial NCT00975000?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2009-12-03. Estimated completion is 2013-04-16.
What interventions are being tested in trial NCT00975000?
The interventions under investigation include: Placebo (DRUG), Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT00975000?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00975000's enrollment target sits among peer trials
114 1648th of 2000 higher than 350 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI